Table 4.
Paul et al [11] Desirability of Outcome Ranking Endpoint With Distribution by Treatment Group
| Paul et al [11] DOOR Endpoint | DOOR Distribution | Partial Credit Score | ||||||
|---|---|---|---|---|---|---|---|---|
| Rank | Alive | How Many of the Following: Treatment Failure Infectious Complications Grade 4 Adverse Events |
TMP/SMX (n = 41) | Vancomycin (n = 50) | Scenario A | Scenario B | Scenario C | Scenario D |
| 1 | Yes | 0 of 3 | 16 (39%) | 21 (42%) | 100 | 100 | 100 | 100 |
| 2 | Yes | 1 of 3 | 9 (22%) | 18 (36%) | 100 | 0 | 100 | 75 |
| 3 | Yes | 2 of 3 | 2 (5%) | 1 (2%) | 100 | 0 | 0 | 50 |
| 4 | Yes | 3 of 3 | 0 (0%) | 1 (2%) | 100 | 0 | 0 | 25 |
| 5 | No (death) | Any | 14 (34%) | 9 (18%) | 0 | 0 | 0 | 0 |
| DOOR Results | Partial Credit Results | |||||||
| Probability (95% CI) of a Higher DOOR Using TMP/SMX Therapy vs Vancomycin Therapy | Estimated Between-treatment Partial Credit Difference a,b (95% CI) | |||||||
| A | B | C | D | |||||
| 0.44 (0.32, 0.55) | –16.2 (–34, 2) | –3.0 (–24, 18) | –17.0 (–36, 2) | –12.6 (–29, 4) | ||||
| P = .09 | P = .83 | P = .11 | P = .28 | |||||
DOOR probability and partial credit scenarios are presented.
Abbreviations: CI, confidence interval; DOOR, desirability of outcome ranking; SMX, sulfamethoxazole; TMP, trimethoprim.
a Estimated between-treatment difference is equal to mean TMP/SMX score minus mean vancomycin score.
b Exact Wilcoxon P values are presented for scenarios A through D. P values using t test ranged from 0.08 to 0.78.